News and Insights

Achieving Market Access

Optimizing Global Launch Sequencing

Traditionally, launch sequencing has been guided by market size, eligible patient population, and the likelihood of securing market access and adoption. While these criteria are still important, they’re no longer sufficient. Growing budget constraints, more stringent evidence requirements, and the rise of external reference pricing and transparency are forcing pharma…

Transatlantic Perspectives on the Future of Pharma

For years, lawmakers have targeted the pharmaceutical industry, blaming it for the high cost of healthcare – its role in the management of Covid-19 notwithstanding.  Despite recent breakthroughs to rid the world of its worst scourges, both the U.S. and EU appear to regard pharma as the single worst actor…

Engaging in Value-Based Contracts with Providers

Pharmaceutical Executive

With spiraling cost inflation and outcomes that lag many other developed economies, the US government’s healthcare insurance authority (CMS), is driving reform aimed at better quality and lower cost, and private payers are following suit. Both state and private payers are moving toward alternative payment models, like value-based payments, that…

The Role of Post-Market Studies in Market Access

eyeforpharma

As payers and providers continue to explore ways to reduce healthcare spending and improve patient outcomes, there is a growing trend to require more evidence of product safety and effectiveness across the product lifecycle.  For manufacturers, the failure to develop such data can result in reduced formulary access and lower…

The Evolving War on Drug Prices

BioPharm International

Over the past few years, the war on drug prices has intensified and been marked by a series of signal events—for example, oncologists publically refusing to allow a pricey new therapy such as Sanofi’s Zaltrap on their formulary, and pharmacy benefit managers (PBMs) (e.g., Express Scripts) and governments (e.g., the…